CLK1/2-IN-3

Cat. No.:	HY-113831
CAS No.:	1005784-60-0
Molecular Formula:	$C_{21}H_{21}N_5O_2$
Molecular Weight:	375.42
Target:	CDK; SRPK
Pathway:	Cell Cycle/DNA Damage
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	LK1/2-IN-3 (compound 3) is a potent and selective CLK1 and CLK2 inhibitor with IC_{50} values of 1.1, 2.1, 130, 260, 260 nM for CLK1, CLK2, SRPK1, SRPK2, SRPK3, respectively. CLK1/2-IN-3 shows anti-proliferative activity. CLK1/2-IN-3 reduces the levels of endogenous phosphorylated SR proteins and increases the expression of S6K mRNAs[1].

IC_{50} & Target				
	CLK1 1.1 nM (IC_{50})	CLK2 2.1 nM (IC_{50})	SRPK1 130 nM (IC_{50})	SRPK2 260 nM (IC_{50})
	SRPK3 260 nM (IC_{50})			

In Vitro	
	CLK1/2-IN-3 (compound 3) (1.1-3.3 μM; 72 h) increases the expression of S6K mRNAs in MDA-MB-468 cells[1]. CLK1/2-IN-3 (5 μM) significantly reduces the levels of endogenous phosphorylated SR proteins[1]. CLK1/2-IN-3 (1-10 μM) shows anti-proliferative activity with GI_{50}s of 3.4, 2.6, 2.1, 2.5, 2.2, 2.9, 1.5 μM for MDA-MB-468, A549, COLO205, HCT-116, NCI-H23, SW620, COLO320DM cells, respectively[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Araki S, et al. Inhibitors of CLK protein kinases suppress cell growth and induce apoptosis by modulating pre-mRNA splicing. PLoS One. 2015;10(1):e0116929. Published 2015 Jan 12.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA